CPTech Page on the US-Australia Free Trade Agreement

Eli Lilly Sues Australia for FTA Violations Regarding Osteoporosis Drug

Pharmaceutical Industry Seeks to have Anti-Evergreening Laws Repealed
PhRMA Documents

US government Documents

Controversy over the Australian Pharmaceutical Benefits Advisory Committe

Summary: The Australian government subsidizes the purchase of a number of drugs, which highly influences the national sales of those drugs. In order for sales of a certain drug to be subsidized, that drug must be listed on the government's Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory Committee (PBAC) is the body which decides which drugs will be included in the PBS. Recently, former pharmaceutical industry lobbyist Pat Clear was appointed a member of the PBAC. The Chairman of the PBAC, Professor Don Birkitt, resigned in protest. Listed below are news stories concerning the controversy:

News Stories

CPT home page IP and health care